NASDAQ : MBRX
Moleculin Biotech, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 8.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 8.49M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 9.14M | 9.12M | 8.79M | 10.02M | 11.54M | 8.39M |
| Research & Development | 19.68M | 15.89M | 17.73M | 19.49M | 18.97M | 14.42M |
| Operating Expenses | 28.88M | 25.10M | 26.64M | 29.63M | 30.64M | 22.97M |
| Operating Income | -28.88M | -25.10M | -26.64M | -29.63M | -30.64M | -22.97M |
| Interest Expense | -43.00K | |||||
| Interest & Investment Income | 49.00K | 105.00K | 550.00K | 1.37M | 240.00K | 306.00K |
| Other Non Operating Income (Expenses) | -1.46M | -8.56M | 43.00K | -1.51M | 1.38M | 6.77M |
| EBT Excluding Unusual Items | -30.33M | -33.56M | -26.05M | -29.77M | -29.02M | -15.89M |
| Pretax Income | -30.33M | -33.56M | -26.05M | -29.77M | -29.02M | -15.89M |
| Net Income | -30.33M | -33.56M | -26.05M | -29.77M | -29.02M | -15.89M |
| Preferred Dividends & Other Adjustments | 2.20M | 104.00K | ||||
| Net Income to Common | -32.52M | -33.66M | -26.05M | -29.77M | -29.02M | -15.89M |
| Shares Outstanding (Basic) | 169.45K | 59.23K | ||||
| Shares Outstanding (Diluted) | 169.45K | 59.23K | ||||
| EPS (Basic) | -191.95 | -568.38 | ||||
| EPS (Diluted) | -191.95 | -568.38 | ||||
| Free Cash Flow | -25.36M | -22.73M | -23.88M | -23.71M | -27.71M | -18.97M |
| Free Cash Flow Per Share | -149.64 | -383.86 | ||||
| EBITDA | -28.83M | -25.01M | -26.52M | -29.50M | -30.51M | -22.80M |
| D&A For EBITDA | 47.00K | 90.00K | 126.00K | 127.00K | 130.00K | 164.00K |
| EBIT | -28.88M | -25.10M | -26.64M | -29.63M | -30.64M | -22.97M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 7.26M | 8.88M | 4.28M | 23.55M | 43.15M | 70.90M |
| Cash & Short-Term Investments | 7.26M | 8.88M | 4.28M | 23.55M | 43.15M | 70.90M |
| Other Receivables | 4.00K | 7.00K | 20.00K | 99.00K | 22.00K | 45.00K |
| Receivables | 4.00K | 7.00K | 20.00K | 99.00K | 22.00K | 45.00K |
| Prepaid Expenses | 1.07M | 523.00K | 565.00K | 2.08M | 1.63M | 1.06M |
| Other Current Assets | 388.00K | 278.00K | 331.00K | 545.00K | 801.00K | 486.00K |
| Total Current Assets | 8.72M | 9.69M | 5.19M | 26.27M | 45.60M | 72.50M |
| Property, Plant & Equipment | 316.00K | 392.00K | 583.00K | 796.00K | 678.00K | 445.00K |
| Other Intangible Assets | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M |
| Other Long-Term Assets | 900.00K | 900.00K | ||||
| Total Assets | 21.09M | 22.13M | 16.93M | 38.22M | 57.42M | 84.09M |
| Accounts Payable | 4.34M | 3.51M | 2.03M | 2.50M | 2.10M | 1.36M |
| Accrued Expenses | 4.83M | 3.21M | 3.21M | 4.22M | 2.61M | 2.16M |
| Current Portion of Leases | 145.00K | 137.00K | 120.00K | 100.00K | 116.00K | 96.00K |
| Total Current Liabilities | 9.31M | 6.85M | 5.36M | 6.82M | 4.82M | 3.62M |
| Long-Term Leases | 147.00K | 222.00K | 358.00K | 474.00K | 335.00K | 63.00K |
| Other Long-Term Liabilities | 40.00K | 44.00K | 4.86M | 77.00K | 1.41M | |
| Total Liabilities | 9.50M | 7.12M | 5.72M | 12.14M | 5.23M | 5.10M |
| Common Stock | 7.00K | 3.00K | 33.00K | 29.00K | 29.00K | |
| Additional Paid-In Capital | 238.13M | 221.00M | 183.69M | 157.65M | 153.99M | 151.73M |
| Retained Earnings | -226.48M | -206.00M | -172.44M | -131.60M | -101.83M | -72.81M |
| Comprehensive Income & Other | -64.00K | 10.00K | -41.00K | -9.00K | 12.00K | 41.00K |
| Shareholders' Equity | 11.59M | 15.01M | 11.21M | 26.07M | 52.19M | 78.99M |
| Total Liabilities & Equity | 21.09M | 22.13M | 16.93M | 38.22M | 57.42M | 84.09M |
| Total Debt | 292.00K | 359.00K | 478.00K | 574.00K | 451.00K | 159.00K |
| Net Cash (Debt) | 6.97M | 8.52M | 3.80M | 22.98M | 42.69M | 70.74M |
| Net Cash Per Share | 41.13 | 143.83 | ||||
| Filing Date Shares Outstanding | 973.87K | 266.82K | 28.00K | |||
| Total Common Shares Outstanding | 355.00K | 159.96K | ||||
| Working Capital | -590.00K | 2.83M | -165.00K | 19.46M | 40.78M | 68.88M |
| Book Value Per Share | 32.64 | 93.81 | ||||
| Tangible Book Value | 439.00K | 3.86M | 60.00K | 14.93M | 41.04M | 67.84M |
| Tangible Book Value Per Share | 1.24 | 24.12 | ||||
| Machinery | 1.18M | 1.16M | 1.17M | 1.04M | 976.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -30.33M | -33.56M | -26.05M | -29.77M | -29.02M | -15.89M |
| Depreciation & Amortization | 47.00K | 90.00K | 126.00K | 127.00K | 130.00K | 164.00K |
| Stock-Based Compensation | 1.58M | 1.66M | 1.73M | 1.98M | 2.27M | 2.37M |
| Other Operating Activities | 1.35M | 8.52M | 103.00K | 2.44M | -1.24M | -6.63M |
| Change in Accounts Payable | 633.00K | 1.33M | -468.00K | 403.00K | 731.00K | 235.00K |
| Change in Other Net Operating Assets | 1.36M | -775.00K | 699.00K | 1.22M | -507.00K | 803.00K |
| Operating Cash Flow | -25.36M | -22.73M | -23.86M | -23.59M | -27.64M | -18.95M |
| Capital Expenditures | -13.00K | -124.00K | -67.00K | -19.00K | ||
| Investing Cash Flow | -13.00K | -124.00K | -67.00K | -19.00K | ||
| Issuance of Common Stock | 25.09M | 27.29M | 4.66M | 4.17M | 74.75M | |
| Repurchase of Common Stock | -8.00K | -8.00K | -26.00K | -25.00K | -23.00K | -23.00K |
| Financing Cash Flow | 25.09M | 27.28M | 4.63M | 4.14M | -23.00K | 74.72M |
| Foreign Exchange Rate Adjustments | -25.00K | 51.00K | -32.00K | -21.00K | -29.00K | -24.00K |
| Net Cash Flow | -295.00K | 4.60M | -19.27M | -19.59M | -27.76M | 55.73M |
| Free Cash Flow | -25.36M | -22.73M | -23.88M | -23.71M | -27.71M | -18.97M |
| Free Cash Flow Per Share | -149.64 | -383.86 | ||||
| Levered Free Cash Flow | -14.92M | -12.26M | -14.36M | -14.60M | -16.09M | -10.17M |
| Unlevered Free Cash Flow | -14.89M | -12.26M | -14.36M | -14.60M | -16.09M | -10.17M |
| Change in Working Capital | 1.99M | 555.00K | 231.00K | 1.62M | 224.00K | 1.04M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 7.69M | 10.19M | 5.10M | 28.68M | 30.35M | 53.15M |
| Enterprise Value | 723.57K | 3.88M | -3.80M | 4.69M | -19.57M | -21.84M |
| Last Close Price | 7.90 | 66.20 | 850.00 | 6,438.00 | 7,950.00 | 13,949.99 |
| PB Ratio | 0.24 | 0.68 | 0.46 | 1.10 | 0.58 | 0.67 |
| P/TBV Ratio | 17.53 | 2.64 | 85.04 | 1.92 | 0.74 | 0.78 |
| Debt / Equity Ratio | 0.03 | 0.02 | 0.04 | 0.02 | 0.01 | 0.00 |
| Net Debt / Equity Ratio | -0.60 | -0.57 | -0.34 | -0.88 | -0.82 | -0.90 |
| Net Debt / EBITDA Ratio | 0.24 | 0.34 | 0.14 | 0.78 | 1.40 | 3.10 |
| Net Debt / FCF Ratio | 0.28 | 0.38 | 0.16 | 0.97 | 1.54 | 3.73 |
| Quick Ratio | 0.78 | 1.30 | 0.80 | 3.47 | 8.96 | 19.59 |
| Current Ratio | 0.94 | 1.41 | 0.97 | 3.85 | 9.46 | 20.02 |
| Return on Equity (ROE) | -1,371.64% | -256.05% | -139.74% | -76.07% | -44.25% | -32.86% |
| Return on Assets (ROA) | -84.57% | -80.35% | -60.39% | -38.73% | -27.07% | -25.38% |
| Return on Capital Employed (ROCE) | -245.20% | -164.40% | -230.30% | -94.40% | -58.20% | -28.50% |
| Earnings Yield | -2,429.69% | -329.27% | -510.49% | -103.79% | -95.65% | -29.90% |
| FCF Yield | -329.59% | -223.06% | -467.90% | -82.69% | -91.30% | -35.69% |